Pangaea Oncology, S.A. (BME:PANG)
Spain flag Spain · Delayed Price · Currency is EUR
1.700
0.00 (0.00%)
At close: Dec 5, 2025

Pangaea Oncology Company Description

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries.

It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation.

The company also provides biomarker discovery to improve treatment through identification of novel theranostic biomarkers.

Pangaea Oncology, S.A. was incorporated in 2006 and is based in Barcelona, Spain.

Pangaea Oncology, S.A.
CountrySpain
Founded2006
IndustryDiagnostics & Research
SectorHealthcare
Employees149
CEOJavier Rivela-Rodriguez

Contact Details

Address:
Sabino Arana, 5-19
Barcelona, 08028
Spain
Phone34 93 409 79 81
Websitepanoncology.com

Stock Details

Ticker SymbolPANG
ExchangeMadrid Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyEUR
ISIN NumberES0105221008
SIC Code2836

Key Executives

NamePosition
Javier Rivela-Rodriguez C.F.A., M.B.A.Co-Founder, Chief Executive Officer and Director
Dr. Rafael Rosell Costa M.D., Ph.D.Chief Scientific Officer, Director, President and Member of Scientific Committee
Alejandro Garcia Moncayo M.B.A.Executive Director of Corporate and Chief Financial Officer
Carmen AlbiolHead of Operations for IOR
Dr. Miguel Angel Molina B.Sc., Ph.D.Executive Director of Research and Development and Member of Scientific Committee
Alejandro Martinez M.D.Chief Medical Officer and Medical Director at IOR (Hospital Universitari Dexeus)
Cristina Masferrer EMBAChief Business Officer